Hélène Font1, Jean-Luc Roelandt2, Hélène Behal3, Pierre-Alexis Geoffroy4,5, Baptiste Pignon6,7,8,9, Ali Amad10,11, Nicolas Simioni12, Guillaume Vaiva10,11, Pierre Thomas10,11, Alain Duhamel3, Imane Benradia2, Benjamin Rolland10,13,14,15. 1. Centre Collaborateur de l'Organisation Mondiale de la Santé, 211 rue Roger Salengro, 59 260, Hellemmes, France. helene.font63@gmail.com. 2. Centre Collaborateur de l'Organisation Mondiale de la Santé, 211 rue Roger Salengro, 59 260, Hellemmes, France. 3. Département de Biostatistiques, Univ. Lille, CHU Lille, EA 2694, Santé publique: épidémiologie et qualité des soins, Lille, France. 4. AP-HP, GH Saint-Louis, Lariboisière, Fernand Widal, Pôle Neurosciences, Paris, France. 5. Université Paris Diderot, UMR-S 1144, Paris, France. 6. AP-HP, DHU PePSY, Hôpitaux Universitaires Henri Mondor, Pôle Psychiatrie Addictologie, Créteil, France. 7. INSERM, U955, équipe 15, Créteil, France. 8. Fondation FondaMental, Créteil, France. 9. UPEC, Université Paris-Est, Faculté de médecine, Créteil, France. 10. Pôle de Psychiatrie et Addictologie, CHRU de Lille, Lille, France. 11. UMR9193-PsychiC-SCALab, Department of Psychiatry, Univ. Lille, CNRS, CHU de Lille, Lille, France. 12. Fondation Phénix, Centre Phénix Plainpalais, Geneva, Switzerland. 13. INSERM U1171, Univ Lille, Lille, France. 14. Service Universitaire d'Addictologie de Lyon (SUAL), CH Le Vinatier, Bron, France. 15. Université de Lyon, UCBL, Lyon, France.
Abstract
PURPOSE: No lifetime utilization of mental health treatment (NUMT) is an indicator of the treatment gap among people in need of treatment. Until now, the overall prevalence and predictors of NUMT have never been explored in France. METHODS: In a 39,617-respondent survey, participants were assessed for NUMT, i.e., no lifetime psychotherapy, psychopharmacotherapy, or psychiatric hospitalization. Mental disorders were investigated using the Mini International Neuropsychiatric Interview (MINI 5.0.0). MINI diagnoses were grouped into five categories: mood disorders (MDs); anxiety disorders (ADs); alcohol use disorders (AUDs); substance use disorders (SUDs); and psychotic disorders (PDs). Using multivariable logistic regression models, we explored the factors associated with NUMT among the MINI-positive respondents. The odds ratio and 95% confidence interval were calculated for each factor. RESULTS: In total, 12,818 (32.4%) respondents were MINI-positive, 46.5% of them reported NUMT (35.6% for MDs, 39.7% for PDs, 42.8% for ADs, 56.0% for AUDs, and 56.7% for SUDs). NUMT was positively associated with being male [OR 1.75 (1.59-1.91)] and practising religion [OR 1.13 (1.02-1.25)] and negatively associated with ageing [per 10-year increase: OR 0.88 (0.85-0.91)], being single [OR 0.74 (0.66-0.84)], being a French native [OR 0.67 (0.60-0.75)], and experiencing MDs [OR 0.39 (0.36-0.43)], ADs [OR 0.47 (0.43-0.52)], AUDs [OR 0.83 (0.73-0.96)], SUDs [OR 0.77 (0.65-0.91)], or PDs [OR 0.50 (0.43-0.59)]. CONCLUSIONS: In France, NUMT rates were the highest for AUDs and SUDs. Additionally, suffering from MDs or ADs increased the lifetime treatment utilization for people having any other mental disorder. This finding emphasizes the need to better screen AUDs and SUDs among people treated for MDs or ADs.
PURPOSE: No lifetime utilization of mental health treatment (NUMT) is an indicator of the treatment gap among people in need of treatment. Until now, the overall prevalence and predictors of NUMT have never been explored in France. METHODS: In a 39,617-respondent survey, participants were assessed for NUMT, i.e., no lifetime psychotherapy, psychopharmacotherapy, or psychiatric hospitalization. Mental disorders were investigated using the Mini International Neuropsychiatric Interview (MINI 5.0.0). MINI diagnoses were grouped into five categories: mood disorders (MDs); anxiety disorders (ADs); alcohol use disorders (AUDs); substance use disorders (SUDs); and psychotic disorders (PDs). Using multivariable logistic regression models, we explored the factors associated with NUMT among the MINI-positive respondents. The odds ratio and 95% confidence interval were calculated for each factor. RESULTS: In total, 12,818 (32.4%) respondents were MINI-positive, 46.5% of them reported NUMT (35.6% for MDs, 39.7% for PDs, 42.8% for ADs, 56.0% for AUDs, and 56.7% for SUDs). NUMT was positively associated with being male [OR 1.75 (1.59-1.91)] and practising religion [OR 1.13 (1.02-1.25)] and negatively associated with ageing [per 10-year increase: OR 0.88 (0.85-0.91)], being single [OR 0.74 (0.66-0.84)], being a French native [OR 0.67 (0.60-0.75)], and experiencing MDs [OR 0.39 (0.36-0.43)], ADs [OR 0.47 (0.43-0.52)], AUDs [OR 0.83 (0.73-0.96)], SUDs [OR 0.77 (0.65-0.91)], or PDs [OR 0.50 (0.43-0.59)]. CONCLUSIONS: In France, NUMT rates were the highest for AUDs and SUDs. Additionally, suffering from MDs or ADs increased the lifetime treatment utilization for people having any other mental disorder. This finding emphasizes the need to better screen AUDs and SUDs among people treated for MDs or ADs.
Authors: Tangui Barré; Fabienne Marcellin; Vincent Di Beo; Jessica Delorme; Teresa Rojas Rojas; Philippe Mathurin; Camelia Protopopescu; François Bailly; Marion Coste; Nicolas Authier; Maria Patrizia Carrieri; Benjamin Rolland Journal: Addiction Date: 2019-11-20 Impact factor: 6.526
Authors: Gerhard Müller; Manuela Bombana; Monika Heinzel-Gutenbrenner; Nikolaus Kleindienst; Martin Bohus; Lisa Lyssenko; Ruben Vonderlin Journal: BMC Public Health Date: 2021-03-31 Impact factor: 3.295
Authors: Kamila Angelika Hynek; Anna-Clara Hollander; Aart C Liefbroer; Lars Johan Hauge; Melanie Lindsay Straiton Journal: Front Public Health Date: 2022-01-07
Authors: Renaud de Beaurepaire; Julia M A Sinclair; Mathis Heydtmann; Giovanni Addolorato; Henri-Jean Aubin; Esther M Beraha; Fabio Caputo; Jonathan D Chick; Patrick de La Selle; Nicolas Franchitto; James C Garbutt; Paul S Haber; Philippe Jaury; Anne R Lingford-Hughes; Kirsten C Morley; Christian A Müller; Lynn Owens; Adam Pastor; Louise M Paterson; Fanny Pélissier; Benjamin Rolland; Amanda Stafford; Andrew Thompson; Wim van den Brink; Lorenzo Leggio; Roberta Agabio Journal: Front Psychiatry Date: 2019-01-04 Impact factor: 4.157